Which is better, HRMY or INCY?

On the Buffett-Fit framework, Harmony Biosciences Holdings, Inc. (HRMY) currently grades higher than INCY — 67/100 (B grade) vs 63/100 (C). That said, "better" depends on which framework you trust — HRMY wins on Warren Buffett, Philip Fisher, Peter Lynch, Charlie Munger, and Terry Smith; INCY wins on Benjamin Graham and Joel Greenblatt. The full pillar breakdown is on this page.

Should I buy HRMY or INCY?

This page is an educational comparison, not investment advice. Both HRMY and INCY are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is HRMY better than INCY for value investing?

The two are close on the headline Buffett-Fit score (67/100 vs 63/100), so "better for value investing" depends on which pillar you weight most. The five Buffett pillars + six other frameworks are broken down side-by-side on this page so you can pick the one that fits your style.

What's the difference between HRMY and INCY on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). HRMY currently scores 67/100 (B grade); INCY scores 63/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, HRMY or INCY?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. HRMY and INCY are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, HRMY or INCY?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are HRMY and INCY both Healthcare stocks?

Yes — both Harmony Biosciences Holdings, Inc. (HRMY) and Incyte Corporation (INCY) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this HRMY vs INCY comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Harmony Biosciences Holdings

Incyte

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

HRMY

Market cap

$1.75B

Sector

Healthcare

INCY

Incyte

Market cap

$19.46B

Sector

Healthcare

Overall winner

Harmony Biosciences Holdings HRMY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	HRMY	INCY	Winner
Warren Buffett	67B	63C	HRMY
Benjamin Graham	60C	73B	INCY
Philip Fisher	75B	61C	HRMY
Peter Lynch	62C	50C	HRMY
Joel Greenblatt	28F	45D	INCY
Charlie Munger	62C	60C	HRMY
Terry Smith	67B	66B	HRMY

Side-by-side metrics

Metric	HRMY	INCY
Market cap	$1.75B	$19.46B
P/E (TTM)	11.8x	14.0x
EV/EBIT	6.4x	12.4x
ROIC (TTM)	12.5%	19.98%
Gross margin	76.55%	91.86%
Net margin	16.2%	26.71%
Revenue CAGR 5y	29.85%	14.55%
EPS CAGR 5y	46.45%	11.26%
Debt / Equity	0.2x	0.0x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

HRMY leads on

EPS CAGR 5y46.45%vs 11.26%+76%
Revenue CAGR 5y29.85%vs 14.55%+51%
EV/EBIT6.4xvs 12.4x+48%
P/E (TTM)11.8xvs 14.0x+15%

INCY leads on

Debt / Equity0.0xvs 0.2x+97%
Market cap$19.46Bvs $1.75B+91%
Net margin26.71%vs 16.2%+39%
ROIC (TTM)19.98%vs 12.5%+37%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Harmony Biosciences Holdings

Incyte

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like HRMY

More like INCY

Related on invest-like

Key terms in this analysis